Suspicion of drug-drug interaction between high-dose methotrexate and proton pump inhibitors: A case report - Should the practice be changed?

Chemotherapy

Volumn 57, Issue 3, 2011, Pages 225-229

  Ranchon, F ^a   Vantard, N ^a   Gouraud, A ^c   Schwiertz, V ^a   Franchon, E ^a   Pham, B N ^a   Vial, T ^c   You, B ^b,d   Bouafia, F ^b   Salles, G ^b,e   Rioufol, C ^a,b,d  

^a Clinical Oncology   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c Centre de Pharmacovigilance de Lyon   (France)

^d UNIVERSITÉ LYON 1   (France)

^e UNIVERSITÉ DE LYON   (France)

Author keywords

Clinical pharmacy; Drug drug interaction; Methotrexate; Proton pump inhibitor

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUOXETINE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; VALACICLOVIR; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; PRIORITY JOURNAL; T CELL LYMPHOMA; T LYMPHOBLASTIC LYMPHOMA;

EID: 79955948735     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000327372     Document Type: Article

References (31)

1. Treon SP, Chabner BA: Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-1329. (Pubitemid 26265051)
2. Faltaos WD, Hulot JS, Urien S, Morel V, Kaloshi G, Fernandez C, et al: Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy. Cancer Chemother Pharmacol 2006;58:626-633. (Pubitemid 44167388)
3. Schwartz S, Borner K, Muller K, Martus P, Fischer L, Korfel A, et al: Glucarpidase (car-boxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist 2007;12:1299-1308. (Pubitemid 350232603)
4. Thyss A, Milano G, Kubar J, Namer M, Schneider M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1986;1:256-258. (Pubitemid 16132863)
5. Aherne GW, Marks V, Mould GP, Piall E, White WF: The interaction between metho-trexate and probenecid in man. Br J Pharmacol 1978;63:369.
6. Zarychanski R, Wlodarczyk K, Ariano R, Bow E: Pharmacokinetic interaction between methotrexate and piperacillin/tazo-bactam resulting in prolonged toxic concentrations of methotrexate. Antimicrob Chemother 2006;58:228-230. (Pubitemid 44295021)
7. Ronchera CL, Hernández T, Peris JE, Torres F, Granero L, Jiménez NV, Plá JM: Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther Drug Monit 1993;15:375-379. (Pubitemid 23297239)
8. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesúmega L, Giráldez J: Potential interaction between methotrexate and omepra-zole. Ann Pharmacother 2000;34:1024-1027.
9. Reid T, Yuen A, Catolico M, Carlson RW: Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 1993;33:82-84. (Pubitemid 23336506)
10. Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H, Meyer FP: Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 2002;324:1497. (Pubitemid 34666620)
11. Bauters TG, Verlooy J, Robays H, Laureys G: Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci 2008;30:316-318.
12. Kolli VK, Abraham P, Isaac B, Selvakumar D: Neutrophil infiltration and oxidative stress may play a critical role in methotrex-ate-induced renal damage. Chemotherapy 2009;55:83-90.
13. Widemann BC, Adamson PC: Understanding and managing methotrexate nephrotox-icity. Oncologist 2006;11:694-703.
14. Reutenauer S, Chauveau D, Récher C: Highdose methotrexate: toxicity, management and prevention. Reanimation 2009;18:654-658.
15. Santucci R, Levêque D, Kemmel V, Lutz P, Gérout AC, N'Guyen A, et al: Severe intoxication with methotrexate possibly associated with concomittant use of proton pump inhibitors. Anticancer Res 2010;30:963-965.
16. Turello R, Rentsch K, Di Paolo E, Popovic MB: Renal failure after high dose methotrexate in a child homozygous for MTHFR C677T polymorphism. Pediatr Blood Cancer 2008;50:154-156. (Pubitemid 350234289)
17. Ulrich CM, Yasui Y, Storb R, Schubert MM, Wagner JL, Bigler J, et al: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-234.
18. Toffoli G, Veronesi A, Boiocchi M, Crivellari D: MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000;11:373-374. (Pubitemid 30214680)
19. Toffoli G, Russo A, Innocenti F, Corona G, Tumolo S, Sartor F, et al: Ef fect of met hylene-tetrahydrofolate reductase 677C → T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003;103:294-299. (Pubitemid 36076421)
20. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N: Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-190. (Pubitemid 34596782)
21. Van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al: The C677T mutation in the methylenetetrahy-drofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-2530. (Pubitemid 33049330)
22. De Mattia E, Toffoli G: C677T and A1298C MTHFR polymorphisms, a challenge for an-tifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009;45:1333-1351.
23. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al: Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007;52:166-171. (Pubitemid 46188292)
24. Whelan J, Hoare D, Leonard P: Omeprazole does not alter plasma methotrexate clearance. Cancer Chemother Pharmacol 1999;44:88-89. (Pubitemid 29246330)
25. Breedveld P, Zelcer N, Pluim D, Sön mezer O, Tibben MM, Beijnen JH, et al: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004;64:5804-5811. (Pubitemid 39095580)
26. Joerger M, Huitema AD, Van Den Bongard HJ, Baas P, Schornagel JH, Schellens JH, et al: Determinants of the elimination of metho-trexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer pat ients. Br J Clin Pharmacol 2006;62:71-80. (Pubitemid 44195244)
27. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Coadministration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 2009;67:44-49.
28. Astrand B: Avoiding drug-drug interactions. Chemotherapy 2009;55:215-220.
29. Maliepaard M, Scheffer GL, Faneyte IF, Van Gastelen MA, Pijnenborg AC, Shinkel AH, et al: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464. (Pubitemid 32695041)
30. Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther 2003;304:524-530. (Pubitemid 36152326)
31. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha HS, et al: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 2002;302:666-671. (Pubitemid 34787234)